FindTrial
Sign In

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00036140
Enrollment
Unknown
Registered
2002-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Pharmacia

Brief summary

The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.

Interventions

DRUGInvestigational drug

Sponsors

Pfizer
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Other specific inclusion/

Exclusion criteria

may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: * Eligible patients must be at least 18 years of age with a diagnosis of multiple myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by the doctor during the investigational drug's treatment. * The patient's multiple myeloma must have gotten worse during/after previous chemotherapy was given. * Any side-effects from prior chemotherapy must have subsided * Blood and urine tests must show adequate bone marrow, liver, and kidney function.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026